77 related articles for article (PubMed ID: 21453932)
1. Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials.
Mallinckrodt CH; Tamura RN; Tanaka Y
J Psychiatr Res; 2011 Sep; 45(9):1202-7. PubMed ID: 21453932
[TBL] [Abstract][Full Text] [Related]
2. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
3. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
4. Simple options for improving signal detection in antidepressant clinical trials.
Mallinckrodt CH; Meyers AL; Prakash A; Faries DE; Detke MJ
Psychopharmacol Bull; 2007; 40(2):101-14. PubMed ID: 17514189
[TBL] [Abstract][Full Text] [Related]
5. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
6. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
Welge JA; Keck PE
Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
[TBL] [Abstract][Full Text] [Related]
7. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
8. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL
J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial outcome in neuropathic pain: relationship to study characteristics.
Katz J; Finnerup NB; Dworkin RH
Neurology; 2008 Jan; 70(4):263-72. PubMed ID: 17914067
[TBL] [Abstract][Full Text] [Related]
10. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
Papakostas GI; Fava M
Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
[TBL] [Abstract][Full Text] [Related]
11. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
12. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
13. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders?
Evans KR; Sills T; Wunderlich GR; McDonald HP
J Psychiatr Res; 2004; 38(4):437-44. PubMed ID: 15203296
[TBL] [Abstract][Full Text] [Related]
14. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
Nelson JC
Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
[TBL] [Abstract][Full Text] [Related]
15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
16. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
Brannan SK; Mallinckrodt CH; Detke MJ; Watkin JG; Tollefson GD
J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.
Chen YF; Yang Y; Hung HM; Wang SJ
Contemp Clin Trials; 2011 Jul; 32(4):592-604. PubMed ID: 21540126
[TBL] [Abstract][Full Text] [Related]
18. Placebo or active control trials of antipsychotic drugs?
Fleischhacker WW; Czobor P; Hummer M; Kemmler G; Kohnen R; Volavka J
Arch Gen Psychiatry; 2003 May; 60(5):458-64. PubMed ID: 12742866
[TBL] [Abstract][Full Text] [Related]
19. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
